根据名称进行药物检索

Fluoxetine Capsules and Tablets (PMDD) 与 Imipramine Capsules

Fluoxetine Capsules and Tablets (PMDD) 与 Imipramine Capsules互相作用以及同时服用的可能性。

检测结果:

Fluoxetine Capsules and Tablets (PMDD) <> Imipramine Capsules

现实性: 09.06.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

谈谈你的医生之前使用丙咪嗪和氟西汀。这种结合可能引起镇静作用、口干、视力模糊便秘和尿潴留。你也可能高级别的氟西汀，其中包括改变的意识、混乱、贫穷肌肉的协调、腹部痉挛、颤抖、扩张的学生、出汗、高血压力，并且增加了的心脏跳动。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用药物而不谈论你的医生第一次。

医界专家:

一般避免：共同给予氟西汀可能会显着增加的等离子体浓度的一些三环抗抑郁药(机师). 拟议的机制是氟西汀的抑制作用CYP450 2D6，同工酶负责的新陈代谢的间隙很多的抗抑郁和精神药物。缉获和精神错乱的报道，以及死亡归因于氟西汀致慢性阿米替林的毒性。 Pharmacodynamically，结合氟西汀的(或者任何其他选择性的血清素再吸收抑制剂)和TCA可能会加强风险的血清素综合症，这是一个罕见的，但是严重的和潜在的致命状况的思想导致过度刺激的脑干5HT1A受体。

管理：在一般情况下，使用氟西汀的(或其他Ssri)与机师应该可以避免的，如果可能的话，或其谨慎处理，如果潜在的利益被认为大于风险。药物反应和等离子体TCA级别应监测更密切只要氟西汀是加入或撤离治疗的患者中稳定在他们现有的抗抑郁治疗方案，并TCA剂量调整是必要的。患者应密切监测为的迹象和症状的TCA毒性(例如，镇静、口干、视力模糊便秘、尿潴留)和/或过量的血清素的活动(例如，中枢神经系统烦躁不安，改变意识、混乱、肌阵挛、共济失调、腹部痉挛、次高烧、颤抖、瞳孔扩张、发汗解表、高血压、心动过速). 由于长期的一半生活中的氟西汀及其活动的代谢物，norfluoxetine的风险的相互作用可能会持续几个星期后中止氟西汀。

来源

Preskorn SH, Beber JH, Faul JC, Hirschfeld RM "Serious adverse effects of combining fluoxetine and tricyclic antidepressants." Am J Psychiatry 147 (1990): 532
Bergstrom RF, Peyton AL, Lemberger L "Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction." Clin Pharmacol Ther 51 (1992): 239-48
Paul KL, Bhatara VS "Anticholinergic delerium possibly associated with protriptyline and fluoxetine." Ann Pharmacother 31 (1997): 1260-1
von Ammon Cavanaugh S "Drug-drug interactions of fluoxetine with tricyclics." Psychosomatics 31 (1990): 273-6
Elyazigi A, Chaleby K, Gad A, Raines DA "Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone." J Clin Pharmacol 35 (1995): 17-21
Vaughan DA "Interaction of fluoxetine with tricyclic antidepressants." Am J Psychiatry 145 (1988): 1478
Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI "Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo." J Pharmacol Exp Ther 268 (1994): 1278-83
Muller N, Brockmoller J, Roots I "Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele: a slowly reversible interaction with fluoxetine." Ther Drug Monit 13 (1991): 533-6
Leroi I, Walentynowicz MA "Fluoxetine-imipramine interaction." Can J Psychiatry 41 (1996): 318-9
Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78
Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7
Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995): 783-4
Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
Westermeyer J "Fluoxetine-induced tricyclic toxicity: extent and duration." J Clin Pharmacol 31 (1991): 388-92
DeMaso DR, Hunter TA "Combining fluoxetine with desipramine." J Am Acad Child Adolesc Psychiatry 29 (1990): 151
Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S "Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine." J Clin Psychopharmacol 14 (1994): 90-8
Wilens TE, Biederman J, Baldessarini RJ, McDermott SP, Puopolo PR, Flood JG "Fluoxetine inhibits desipramine metabolism." Arch Gen Psychiatry 49 (1992): 752
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
Downs JM, Downs AD "Effect of fluoxetine on metabolism of tricyclic antidepressants in the lungs." Am J Psychiatry 146 (1989): 814-5
Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3
Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50
Gillman PK "Fluoxetine (prozac)." Med J Aust 159 (1993): 492
Schraml F, Benedetti G, Hoyle K, Clayton A "Fluoxetine and nortriptyline combination therapy." Am J Psychiatry 146 (1989): 1636-7
Ereshefsky L, Riesemman C, Lam YW "Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6." Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5
Taylor D "Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses." Br J Psychiatry 167 (1995): 575-80
Bell IR, Cole JO "Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression." J Clin Psychopharmacol 8 (1988): 447-8
Vandel S, Bertschy G, Bonin B, et al. "Tricyclic antidepressant plasma levels after fluoxetine." Neuropsychobiology 25 (1992): 202-7
Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9
Sternbach H "Fluoxetine-clomipramine interaction." J Clin Psychiatry 56 (1995): 171-2
Preskorn SH, Baker B "Fatality associated with combined fluoxetine-amitryptyline therapy." JAMA 277 (1997): 1682
Downs JM, Dahmer SK "Fluoxetine and elevated plasma levels of tricyclic antidepressants." Am J Psychiatry 147 (1990): 1251
Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
Popli AP, Baldessarini RJ, Cole JO "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 51 (1994): 666-7
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13